ResMed Inc.
Income Statement
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.46B | $1.43B | $1.42B | $1.34B | $1.35B | $1.29B | $1.28B | $1.22B |
| Cost of Revenue | $602.4M | $540.4M | $544.1M | $514.8M | $527.9M | $525.3M | $530.8M | $507.3M |
| Gross Profit | $861.2M | $891.0M | $878.7M | $820.8M | $820.1M | $766.4M | $751.3M | $717.2M |
| Gross Margin | 58.8% | 62.2% | 61.8% | 61.5% | 60.8% | 59.3% | 58.6% | 58.6% |
| Operating Expenses | ||||||||
| Research & Development | $105.7M | $94.3M | $91.0M | $87.3M | $86.4M | $83.9M | $81.4M | $79.5M |
| SG&A Expense | $296.3M | $285.7M | $278.4M | $259.2M | $267.2M | $245.3M | $241.6M | $239.0M |
| Operating Income | $448.7M | $499.8M | $491.7M | $446.5M | $454.5M | $426.3M | $417.2M | $387.3M |
| Operating Margin | 30.7% | 34.9% | 34.6% | 33.4% | 33.7% | 33.0% | 32.5% | 31.6% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | $474.2M | $502.3M | $496.1M | $446.8M | $458.1M | $417.7M | $418.3M | $383.5M |
| Income Tax Expense | $90.7M | $103.6M | $103.6M | $98.3M | $78.3M | $52.7M | $73.7M | $72.1M |
| Net Income | $383.4M | $398.7M | $392.6M | $348.5M | $379.7M | $365.0M | $344.6M | $311.4M |
| Net Margin | 26.2% | 27.9% | 27.6% | 26.1% | 28.2% | 28.3% | 26.9% | 25.4% |
| EPS (Basic) | $2.66 | $2.74 | $2.69 | $2.38 | $2.59 | $2.49 | $2.35 | $2.12 |
| EPS (Diluted) | $2.64 | $2.74 | $2.68 | $2.37 | $2.58 | $2.48 | $2.34 | $2.11 |
| Shares Outstanding (Basic) | 145.5M | 145.3M | 145.8M | 146.2M | 146.7M | 146.7M | 146.8M | 146.9M |
| Shares Outstanding (Diluted) | 146.1M | 145.7M | 146.4M | 146.9M | 147.3M | 147.2M | 147.5M | 147.6M |
| Dividends Per Share | $0.60 | $0.60 | $0.60 | $0.60 | $0.53 | $0.53 | $0.53 | $0.53 |